What Causes Age-Related Macular Degeneration?

Decades of accumulated oxidative stress and chronic inflammation quietly erode the retinal pigment epithelium, the support layer that keeps the macula’s cone photoreceptors alive. Aging, smoking, and inherited variants in the CFH and ARMS2 genes drive that damage, while drusen form as visible debris between the RPE and the choroid. About 200 million people worldwide live with some stage of it, making it the leading cause of irreversible central vision loss in adults over 50.

You will find the cellular chain of events behind AMD here, separated from suspected contributors, so you can see where your effort matters most.

The Macula and the Cellular Breakdown Behind AMD

Your macula sits at the center of the retina, packed with cone photoreceptors that demand enormous oxygen and nutrient flow to deliver fine detail and color. Directly beneath those photoreceptors lies the retinal pigment epithelium (RPE), a single cell layer that recycles visual pigments, digests daily waste, and ferries nourishment from the choroid, the eye’s underlying blood vessel network.

Each photon of light striking the macula creates oxidative byproducts, the same kind of cellular exhaust that rusts metal and browns a cut apple. Over decades, the RPE absorbs more reactive oxygen than its antioxidant defenses can neutralize. Mitochondria inside these cells start to underperform, and damaged proteins, lipids, and cellular debris pile up where photoreceptors once received clean support. Chronic low-grade inflammation, driven in part by the complement immune cascade, accelerates that decline.

That debris forms drusen, the yellowish deposits ophthalmologists flag as the earliest visible hallmark of AMD. Drusen are not AMD, but their presence signals that the RPE is failing and the photoreceptors above are starving. Photoreceptor degeneration follows, and central vision dims, blurs, or develops a blank spot called a scotoma. The whole process moves slowly, often invisible for years until enough central tissue is compromised to interfere with daily tasks.

Dry Versus Wet AMD: Two Stages on the Same Continuum

Dry (atrophic) AMD and wet (neovascular) AMD are not separate diseases; they sit on the same spectrum, distinguished by how far the underlying cellular failure has progressed.

Dry AMD and the Slow Thinning of the Macula

Dry AMD accounts for roughly 85 to 90 percent of cases and progresses through gradual RPE atrophy and photoreceptor loss. Drusen enlarge, coalesce, and the central retina thins over years, so visual decline is usually slow, measured in lines of an eye chart rather than days. Geographic atrophy is the advanced form, where patches of RPE and photoreceptors have died, leaving a sharply defined blind spot in central vision.

Wet AMD and the VEGF-Driven Turn

Wet AMD develops when the starving macula releases a chemical distress signal. Vascular endothelial growth factor (VEGF) surges, and fragile new blood vessels sprout from the choroid, a process called choroidal neovascularization. Those vessels leak fluid or blood directly into the retinal layers, distorting the macula within days or weeks, and untreated wet AMD can destroy central vision far faster than dry AMD ever does.

Why the Distinction Matters

Wet AMD almost always grows out of existing dry AMD rather than appearing on its own. Roughly 10 to 15 percent of dry AMD converts to the wet form in a given eye over time, and once it does, urgent care matters because anti-VEGF therapy works best when delivered early. Knowing where you sit on the continuum shapes how closely you monitor and how aggressively you act on new symptoms.

Proven Drivers of AMD: Smoking, Age, and Genetics

Smoking tops every evidence-based list of modifiable risk factors for macular degeneration, roughly doubling the chance of developing it and accelerating progression in those who already have early signs. Tobacco smoke delivers oxidizing chemicals straight into the bloodstream that reach the choroid and overwhelm the RPE’s antioxidant defenses. Cadmium and other heavy metals in smoke further impair RPE function, and quitting slows the risk trajectory even after a long history of use.

The Risks You Cannot Change

Age remains the single strongest predictor: prevalence climbs sharply past 65 and keeps rising into the 80s. Women develop AMD at higher rates than men, partly because they live longer on average. Lighter eye color (blue or hazel rather than dark brown) and a family history of the disease both raise risk, with a sibling or parent diagnosis roughly tripling your own odds. Light-colored irises may transmit more short-wavelength light to the retina, and inherited variants shape how your complement and inflammatory systems handle retinal debris.

Genes That Load the Gun

Two gene variants carry most of the inherited risk: CFH (complement factor H), which regulates the immune cascade that amplifies retinal inflammation, and ARMS2, which influences mitochondrial function inside the RPE. Variants in these genes can multiply AMD risk by 2 to 6 times, especially when both copies are affected. Family history is not destiny, but it justifies earlier and more frequent dilated exams.

Of these proven drivers, smoking is the only one you can change. Age, sex, eye color, and genetics set the baseline; smoking determines how steeply the curve climbs.

Suspected Contributors and the Oxidative Stress Connection

Cardiovascular factors such as high blood pressure, elevated LDL cholesterol, obesity, and sedentary lifestyle correlate with AMD progression in many observational studies, though the evidence is softer than for smoking. The likely link runs through the same biological pathway: chronic vascular inflammation and reduced choroidal perfusion raise oxidative stress at the macula, accelerating RPE failure. A history of cataract surgery is also linked with modestly higher AMD risk, probably because post-surgical inflammation adds another oxidative hit.

Blue light exposure, low dietary antioxidants, and prolonged systemic inflammation all point in the same direction. The retina is uniquely vulnerable to oxidative stress because its photoreceptor membranes are rich in polyunsaturated fatty acids, which oxidize easily. When your diet lacks leafy greens (lutein and zeaxanthin) and omega-3-rich fish, the raw materials for macular pigment and anti-inflammatory signaling drop. Add chronic inflammation from arthritis, smoking, or poor sleep, and the RPE’s daily repair budget goes into the red.

“For people already carrying high genetic risk, controlling blood pressure and cholesterol matters even more, because each extra source of oxidative stress compounds the inherited load.

These contributors are not proven causes the way smoking is, but they cluster around the same mechanism. That shared through-line is the most useful framing: anything that raises chronic oxidative load or inflammation at the macula can tilt the balance toward drusen formation and RPE death.

Cumulative oxidative burden is what turns suspicion into measurable drusen, the earliest clinical sign worth tracking at home.

Early Warning Signs and How to Self-Monitor With an Amsler Grid

AMD almost never announces itself with pain. The first clues are visual and easy to miss: print that needs brighter light, faces that look smudged across a dinner table, straight doorframes that seem slightly wavy, or colors that appear washed out. Because the brain fills in gaps aggressively, a small central scotoma often goes unnoticed until it crosses the threshold where reading or driving fails.

Using an Amsler Grid the Right Way

An Amsler grid looks like graph paper with a dot in the center. Hold it at reading distance in good light, cover one eye, and stare at the dot. Every line should look straight, every square the same size. Repeat with the other eye, and do this weekly. New waviness, a new blank patch, or a sudden gray haze is the signal to call your eye care professional for a dilated exam, often within days rather than weeks.

Dry Versus Wet Symptom Patterns

Dry AMD symptoms drift: vision blurs over months, colors lose punch, and central detail slowly fades. Wet AMD conversion tends to strike suddenly: a straight line you saw straight yesterday now bows, or a dark blob appears in the center of your sight within a week. Sudden distortion is the one symptom pattern that demands same-day evaluation, because anti-VEGF therapy works best when delivered early.

One reassurance worth holding onto: AMD almost never causes total blindness. Peripheral retina is preserved, so you keep navigation vision and lose the detail at the center, not the world around it.

Slowing AMD: AREDS2 Supplements, Lifestyle Changes, and Treatment Options

The AREDS2 formula, tested in the Age-Related Eye Disease Study 2 and refined from the original AREDS trial, combines high-dose vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin. It does not prevent AMD from starting, but in people with intermediate dry AMD or advanced disease in one eye, it slows progression toward the other eye by roughly 25 percent over five years. That finding, sponsored by the National Eye Institute, is referenced in current American Academy of Ophthalmology practice guidance.

Evidence-Backed Lifestyle Changes

Quitting smoking sits at the top of every list for good reason. Beyond that, the strongest lifestyle signals point toward a Mediterranean-style diet rich in leafy greens, colorful vegetables, and fatty fish, regular aerobic exercise, and tight control of blood pressure and cholesterol. Sunglasses that block UV and blue light outdoors help reduce daily retinal oxidative load. Routine dilated eye exams every one to two years after age 50 catch drusen before they cause symptoms.

Wet AMD and Anti-VEGF Injections

Tiny needles deliver anti-VEGF drugs straight into the vitreous, the gel-filled chamber behind the lens, to shut down the leaking vessels that define wet AMD. These medicines block the VEGF signal that drives abnormal vessel growth, drying up leakage and often stabilizing or improving vision when started early. Frequency varies from monthly to as-needed depending on the drug and response.

Your Next-Step Checklist

• ▸Schedule a dilated exam if you are over 50 and have not had one in the past year.
• ▸Begin weekly Amsler grid checks at home, one eye at a time, in good light.
• ▸Quit smoking or set a quit date, the single highest-impact change you can make.
• ▸Adjust your diet toward leafy greens, fish twice a week, and fewer processed foods.
• ▸Control blood pressure and cholesterol with the help of your primary care team.
• ▸Ask your eye doctor whether AREDS2 supplementation fits your stage of disease.
• ▸Act fast on new distortion, because wet AMD conversion is a same-week, not same-month, situation.

Because every person’s stage and risk profile differ, follow the recommendations of your eye care specialist and primary care physician for the plan that fits your situation.

The Big Picture

Age-related macular degeneration is a decades-long story of accumulated oxidative stress, chronic inflammation, and inherited vulnerability converging on a small patch of retina that runs your central vision. The causes you can modify, especially smoking, diet, and cardiovascular health, sit on top of a baseline risk shaped by age and genes. Early detection through regular dilated exams and weekly Amsler grid use remains your strongest defense, because damage already done cannot be undone, but further loss often can be slowed or stopped.

FAQ